Literature DB >> 19615917

Thymoma and thymic carcinoma.

Federico Venuta1, Marco Anile, Daniele Diso, Domenico Vitolo, Erino A Rendina, Tiziano De Giacomo, Federico Francioni, Giorgio Furio Coloni.   

Abstract

Thymoma and thymic carcinoma are an extremely heterogeneous group of neoplastic lesions with an exceedingly wide spectrum of morphologic appearances. They show different presentations with a variable and unpredictable evolution ranging from an indolent non-invasive attitude to a highly infiltrative and metastasising one. Prognosis can be predicted on the basis of a number of variables, mainly staging, the WHO histological pattern and diameter of the tumour. Complete surgical resection is certainly the gold standard to achieve cure. However, especially in patients with lesions at advanced stage, complete resection may be difficult and recurrence often occurs; at these stages, disease-free long-term survival may be difficult to be accomplished. Chemo- and radiotherapy protocols have been designed to complete surgical treatment and improve results in inoperable patients as well, based on the reported sensitivity of thymic tumours to these treatment modalities. The integration of clinical staging and histology, with the new histogenetic morphological classification, has contributed to design multimodality treatment protocols that help to improve prognosis. Induction therapy can now be applied before surgery in patients with tumours considered inoperable, improving resectability and outcome without adding morbidity and mortality to the surgical procedure. This newly developed approach helps to reduce the recurrence rate and to ameliorate disease-free survival. New therapies are now being evaluated as for many other tumours; however, they still need confirmation in prospective randomised studies. In the future, integrated treatment modality should be incorporated in a standardised approach that goes from a careful assessment of histology, staging and lymph node status, and a constructive and non-empirical co-operation between medical and radiation oncologists, pathologists and thoracic surgeons. Copyright 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19615917     DOI: 10.1016/j.ejcts.2009.05.038

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  55 in total

1.  Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging.

Authors:  Anya M Litvak; Kaitlin Woo; Sara Hayes; James Huang; Andreas Rimner; Camelia S Sima; Andre L Moreira; Maria Tsukazan; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2014-12       Impact factor: 15.609

Review 2.  Thymic tumors and immune checkpoint inhibitors.

Authors:  Shintaro Yokoyama; Hiroaki Miyoshi
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.

Authors:  Dwight Owen; Benjamin Chu; Amy M Lehman; Lakshmanan Annamalai; Jennifer H Yearley; Konstantin Shilo; Gregory A Otterson
Journal:  J Thorac Oncol       Date:  2018-04-24       Impact factor: 15.609

4.  Analysis of CT features and quantitative texture analysis in patients with thymic tumors: correlation with grading and staging.

Authors:  Angelo Iannarelli; Beatrice Sacconi; Francesca Tomei; Marco Anile; Flavia Longo; Mario Bezzi; Alessandro Napoli; Luca Saba; Michele Anzidei; Giulia D'Ovidio; Roberto Scipione; Carlo Catalano
Journal:  Radiol Med       Date:  2018-01-06       Impact factor: 3.469

5.  Texture analysis of 18F-FDG PET/CT for grading thymic epithelial tumours: usefulness of combining SUV and texture parameters.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Tetsuya Shinaji; Masayuki Nakajo; Masaya Aoki; Atsushi Tani; Masami Sato; Takashi Yoshiura
Journal:  Br J Radiol       Date:  2018-01-19       Impact factor: 3.039

6.  Unusual clinical behaviour of thymoma with recurrent myasthenia gravis.

Authors:  Keduovinuo K Keditsu; George Karimundackal; Nirmala A Jambhekar; C S Pramesh
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-28

7.  Multimodality therapy for locally-advanced thymic epithelial tumors: where are we now?

Authors:  Pier Luigi Filosso; Francesco Guerrera; Alberto Sandri; Enrico Ruffini
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 8.  Management of thymic tumors: a European perspective.

Authors:  Enrico Ruffini; Federico Venuta
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

9.  Thymic neoplasm: a rare disease with a complex clinical presentation.

Authors:  Omar M Rashid; Anthony D Cassano; Kazuaki Takabe
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

10.  Thymic carcinomas: clinicopathologic study of 37 cases from a single institution.

Authors:  Vincent Thomas de Montpréville; Maria-Rosa Ghigna; Ludovic Lacroix; Benjamin Besse; Philippe Broet; Philippe Dartevelle; Elie Fadel; Peter Dorfmuller
Journal:  Virchows Arch       Date:  2013-01-15       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.